SANTA CLARA, Calif. (AP) -- Agilent Technologies Inc. has completed its $2.2 billion acquisition of Danish cancer diagnostics company Dako.
Agilent, a scientific instrument maker based in Santa Clara, Calif., announced the deal last month. It purchased Dako from Swedish private equity group EQT and said at that time that the transaction would help it develop a wider range of cancer-fighting products, expand its life sciences division and boost revenue.
Dako provides antibodies, scientific instruments and software mainly to cancer-related diagnostic labs. It also works with drug companies to develop new methods that could be used to identify patients most likely to benefit from certain therapies.
Dako's products are sold in more than 100 countries, and its 2010 revenue totaled about $340 million. It employs more than 1,000 people in Denmark, the U.S. and other parts of the world.
Agilent said Thursday that it has formed a new segment called the diagnostics and genomics group. It will include Dako and the genomics solutions division.
Agilent shares closed at $40.64 on Wednesday. They have traded in a 52-week range of $28.67 to $53.62 per share.